A case for RhD-negative blood in trauma patients who may conceive

Many trauma services now resuscitate with low-titre group O whole blood, which is usually RhD-positive because RhD-negative whole blood is scarce. An RhD-negative patient, or one of unknown type, can develop anti-D after that transfusion, and the harm appears years later as haemolytic disease in a future pregnancy.

This Obstetrics & Gynecology commentary, published on 15 September, argues that accepting this risk depended on whole blood giving a survival advantage. It notes that two recent randomised trials of prehospital haemorrhage found no survival advantage for whole blood over component therapy, and concludes that RhD-positive whole blood is not justified for patients with reproductive potential when compatible products are available.

The authors ask institutions to default such patients to RhD-negative products until the type is confirmed, and to guarantee follow-up when an RhD-incompatible transfusion happens. This is an argued position rather than new outcome data, but it is a conversation obstetricians can start with their transfusion and trauma teams.

• Ask your trauma and transfusion teams which product patients of unknown RhD type receive.
• After any RhD-incompatible transfusion in a woman who may conceive, arrange antibody screening and follow-up.
• In a later pregnancy, ask about past trauma transfusion when anti-D is found without an obstetric cause.
• Record transfusion history clearly in the notes of women of reproductive age.

Why it matters

An obstetric harm is being decided in the resuscitation bay, years before an obstetrician meets it.

Don't overread it

This is an ethics commentary; it reports no new outcome data of its own.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.